Brief: Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences
07/04/2025 21:10
April 7 (Reuters) - Savara Inc SVRA.O: SAVARA ANNOUNCES ENCORE PRESENTATIONS FROM THE PHASE 3 IMPALA-2 TRIAL OF MOLGRAMOSTIM INHALATION SOLUTION (MOLGRAMOSTIM) IN PATIENTS WITH AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP) AT TWO UPCOMING SCIENTIFIC CONFERENCES Source text: ID:nBw4CrZWHa Further company coverage: SVRA.O ((Reuters.Briefs@thomsonreuters.com;))